Verrica Pharmaceuticals (VRCA) said Wednesday it is restructuring its sales and operating teams aimed at reducing costs and expanding access to YCANTH for the treatment of molluscum contagiosum.
The restructuring is expected to lower the company's overall cost structure by around 50% while maintaining adequate resources to support its primary product, YCANTH.
Verrica said it will reduce its number of sales territories from 80 to 35, focusing on regions with a high prevalence of molluscum contagiosum, substantial usage of cantharidin, which is the active ingredient in YCANTH, and strong insurance coverage for the product.
In addition, sales efforts will target both pediatricians and dermatologists to enhance access to YCANTH.
Verrica anticipates a one-time restructuring charge of around $1 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。